UCSF home page UCSF home page About UCSF UCSF Medical Center
UCSF navigation bar

Faculty Profiles

Uma Mahadevan, MD

1701 Divisadero
San Francisco, CA 94115

Dr. Mahadevan completed a medical degree at the State University of New York in Brooklyn. She completed residency in internal medicine at Mount Sinai Medical Center in New York, a fellowship in gastroenterology at the University of California, San Francisco (UCSF) and a fellowship in inflammatory bowel disease (IBD) at the Mayo Clinic in Rochester, Minnesota. Dr. Mahadevan currently serves as Professor of Medicine at UCSF and Medical Director of the UCSF Center for Colitis and Crohn's Disease and is Director of the IBD Fellowship.

Certified by the American Board of Internal Medicine as a Diplomate in internal medicine and gastroenterology, Dr. Mahadevan is a fellow of the American Gastroenterological Association, for whom she is a Vice-Chair for the Clinical Immunology, Microbiology and Inflammatory Bowel Disease (IMIBD) Section and co-director of the 2017 Post-Graduate Course. She is also a fellow of the American College of Gastroenterology for whom she is Chair of IBD for the 2017 ACG/World Congress course and a member of the Educational Affairs Committee. She is currently co-chair of the CCFA Clinical Research Grants committee and a member of the CCFA National Scientific Advisory Committee.

Dr. Mahadevan is an associate editor for Gastroenterology and an editorial board member and reviewer for several other journals. She is currently the editor of a special issue on IBD for 2017. Dr. Mahadevan has published original articles, abstracts, editorials, and invited reviews in such peer-reviewed journals as Gastroenterology, Gut, American Journal of Gastroenterology and Inflammatory Bowel Diseases along with several book chapters.

Dr. Mahadevan specializes in the treatment of ulcerative colitis, Crohn's disease, and pouchitis. She has a particular interest in pregnancy and fertility in IBD, as well as in clinical trials of experimental therapy for both ulcerative colitis and Crohn's disease. Her current projects include a national prospective registry of pregnancy outcomes and drug safety in women with IBD on immunosuppressive and biologic medications (PIANO), clinical trials in biologic therapy for IBD, and microbiome, environmental and dietary changes among patients with IBD.

Education and Training

Location Degree or Training Specialty Date
Mayo Clinic, Rochester, MN Inflammatory Bowel Disease 2001
University of California, San Francisco Gastroenterology 2001
Mount Sinai School of Medicine Internal Medicine 1998
SUNY Brooklyn M.D. 1995


Crohns disease, Inflammatory bowel disease, clinical research, pregnancy, ulcerative colitis

Awards and Honors
2008   Best Doctors in America, 2008-2015

Featured Videos

Related Web Sites

In the News

Recent Articles (85)

Matro R, Martin CF, Wolf D, Shah SA, Mahadevan U. Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development. Gastroenterology. 2018 May 29.

Kattah MG, Milush JM, Burt T, McCabe RP, Whang MI, Ma A, Mahadevan U. Anti-TNF and thiopurine therapy in pregnant IBD patients does not significantly alter a panel of B-cell and T-cell subsets in 1-year-old infants. Clin Transl Gastroenterol. 2018 Apr 03; 9(4):143.

Mahadevan U, Silverberg MS. Inflammatory Bowel Disease-Gastroenterology Diamond Jubilee Review. Gastroenterology. 2018 Mar 15.

Beaulieu DB, Ananthakrishnan AN, Martin C, Cohen RD, Kane SV, Mahadevan U. Use of Biologic Therapy by Pregnant Women With Inflammatory Bowel Disease Does Not Affect Infant Response to Vaccines. Clin Gastroenterol Hepatol. 2018 Jan; 16(1):99-105.

Bengtson MB, Aamodt G, Mahadevan U, Vatn MH. Inadequate Gestational Weight Gain, the Hidden Link Between Maternal IBD and Adverse Pregnancy Outcomes: Results from the Norwegian Mother and Child Cohort Study. Inflamm Bowel Dis. 2017 07; 23(7):1225-1233.

Mahadevan U, Vermeire S, Lasch K, Abhyankar B, Bhayat F, Blake A, Dubinsky M. Editorial: vedolizumab in pregnancy - is gut selectivity as good for baby as it is for mum? Authors' reply. Aliment Pharmacol Ther. 2017 05; 45(9):1284.

Mahadevan U. How to Get an Education in Inflammatory Bowel Disease During Fellowship: Expectations and Realities. Gastroenterology. 2017 Jun; 152(8):1813-1816.

Bengtson MB, Martin CF, Aamodt G, Vatn MH, Mahadevan U. Inadequate Gestational Weight Gain Predicts Adverse Pregnancy Outcomes in Mothers with Inflammatory Bowel Disease: Results from a Prospective US Pregnancy Cohort. Dig Dis Sci. 2017 08; 62(8):2063-2069.

Mahadevan U, Vermeire S, Lasch K, Abhyankar B, Bhayat F, Blake A, Dubinsky M. Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease. Aliment Pharmacol Ther. 2017 04; 45(7):941-950.

Colombel JF, Mahadevan U. Inflammatory Bowel Disease 2017: Innovations and Changing Paradigms. Gastroenterology. 2017 02; 152(2):309-312.

Mahadevan U, McConnell RA, Chambers CD. Drug Safety and Risk of Adverse Outcomes for Pregnant Patients With Inflammatory Bowel Disease. Gastroenterology. 2017 02; 152(2):451-462.e2.

Mar JS, LaMere BJ, Lin DL, Levan S, Nazareth M, Mahadevan U, Lynch SV. Disease Severity and Immune Activity Relate to Distinct Interkingdom Gut Microbiome States in Ethnically Distinct Ulcerative Colitis Patients. MBio. 2016 08 16; 7(4).

McConnell RA, Mahadevan U. The Birds, the Bees, and Inflammatory Bowel Disease: Preconception Care in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2016 Sep; 14(9):1293-5.

Cohan JN, Ozanne EM, Sewell JL, Hofer RK, Mahadevan U, Varma MG, Finlayson E. A Novel Decision Aid for Surgical Patients with Ulcerative Colitis: Results of a Pilot Study. Dis Colon Rectum. 2016 Jun; 59(6):520-8.

McConnell RA, Mahadevan U. Pregnancy and the Patient with Inflammatory Bowel Disease: Fertility, Treatment, Delivery, and Complications. Gastroenterol Clin North Am. 2016 06; 45(2):285-301.

Kathpalia P, Kane S, Mahadevan U. Detectable Drug Levels in Infants Exposed to Biologics: So What? Gastroenterology. 2016 07; 151(1):25-6.

Carlucci JG, Halasa N, Creech CB, Dulek DE, Gómez-Duarte OG, Nelson GE, Talbot HK, Scalise ML, Scott PL, Mahadevan U, Beaulieu DB. Vertical Transmission of Histoplasmosis Associated With Anti-Tumor Necrosis Factor Therapy. J Pediatric Infect Dis Soc. 2016 Jun; 5(2):e9-e12.

Sheibani S, Cohen R, Kane S, Dubinsky M, Church JA, Mahadevan U. The Effect of Maternal Peripartum Anti-TNFa Use on Infant Immune Response. Dig Dis Sci. 2016 06; 61(6):1622-7.

McConnell RA, Mahadevan U. Use of Immunomodulators and Biologics Before, During, and After Pregnancy. Inflamm Bowel Dis. 2016 Jan; 22(1):213-23.

Nguyen GC, Seow CH, Maxwell C, Huang V, Leung Y, Jones J, Leontiadis GI, Tse F, Mahadevan U, van der Woude CJ. The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. Gastroenterology. 2016 Mar; 150(3):734-757.e1.

Mahadevan U, Matro R. In Reply. Obstet Gynecol. 2015 Nov; 126(5):1109.

Clowse ME, Wolf DC, Förger F, Cush JJ, Golembesky A, Shaughnessy L, De Cuyper D, Mahadevan U. Pregnancy Outcomes in Subjects Exposed to Certolizumab Pegol. J Rheumatol. 2015 Dec; 42(12):2270-8.

Mahadevan U, Matro R. Care of the Pregnant Patient With Inflammatory Bowel Disease. Obstet Gynecol. 2015 Aug; 126(2):401-12.

Kattah MG, Mahadevan U. Confocal laser endomicroscopy for membrane-bound tumor necrosis factor predicts response to therapy in Crohn's disease. Gastroenterology. 2015 May; 148(5):1067-9.

Kavanaugh A, Cush JJ, Ahmed MS, Bermas BL, Chakravarty E, Chambers C, Clowse M, Curtis JR, Dao K, Hankins GD, Koren G, Kim SC, Lapteva L, Mahadevan U, Moore T, Nolan M, Ren Z, Sammaritano LR, Seymour S, Weisman MH. Proceedings from the American College of Rheumatology Reproductive Health Summit: the management of fertility, pregnancy, and lactation in women with autoimmune and systemic inflammatory diseases. Arthritis Care Res (Hoboken). 2015 Mar; 67(3):313-25.

Huang VW, Mahadevan U. A measured approach to Crohn's therapy: check levels and save. Gastroenterology. 2014 Nov; 147(5):1174-5.

Lin K, Mahadevan U. Pharmacokinetics of biologics and the role of therapeutic monitoring. Gastroenterol Clin North Am. 2014 Sep; 43(3):565-79.

Kattah MG, Mahadevan U. Insights into the molecular pathophysiology of inflammatory bowel disease: ATG16L1 suppresses nod-driven inflammation. Gastroenterology. 2014 Aug; 147(2):528-30.

Hassid B, Mahadevan U. The use of biologic therapy in pregnancy: a gastroenterologist's perspective. Curr Opin Rheumatol. 2014 May; 26(3):347-53.

Hwang C, Ross V, Mahadevan U. Popular exclusionary diets for inflammatory bowel disease: the search for a dietary culprit. Inflamm Bowel Dis. 2014 Apr; 20(4):732-41.

Shah S, Terdiman J, Gundling K, Mahadevan U. Immunoglobulin therapy for refractory Crohn's disease. Therap Adv Gastroenterol. 2014 Mar; 7(2):99-102.

Ng SW, Mahadevan U. My treatment approach to management of the pregnant patient with inflammatory bowel disease. Mayo Clin Proc. 2014 Mar; 89(3):355-60.

Lin KK, Mahadevan U. Etrolizumab: anti-ß7-a novel therapy for ulcerative colitis. Gastroenterology. 2014 Jan; 146(1):307-9.

Truta B, Li DX, Mahadevan U, Fisher ER, Chen YY, Grace K, Velayos F, Terdiman JP. Serologic markers associated with development of Crohn's disease after ileal pouch anal anastomosis for ulcerative colitis. Dig Dis Sci. 2014 Jan; 59(1):135-45.

Sheibani S, Mahadevan U. Editorial: Are thiopurines and anti-TNFa agents safe to use in pregnant patients with inflammatory bowel disease? Am J Gastroenterol. 2013 Mar; 108(3):441-3.

Ng SW, Mahadevan U. Management of inflammatory bowel disease in pregnancy. Expert Rev Clin Immunol. 2013 Feb; 9(2):161-73; quiz 174.

Akbari M, Shah S, Velayos FS, Mahadevan U, Cheifetz AS. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013 Jan; 19(1):15-22.

Mahadevan U, Wolf DC, Dubinsky M, Cortot A, Lee SD, Siegel CA, Ullman T, Glover S, Valentine JF, Rubin DT, Miller J, Abreu MT. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013 Mar; 11(3):286-92; quiz e24.

Pak S, Holland N, Garnett EA, Mileti E, Mahadevan U, Beckert R, Kanwar B, Heyman MB. Cytokine profiles in peripheral blood of children and adults with Crohn disease. J Pediatr Gastroenterol Nutr. 2012 Jun; 54(6):769-75.

Hwang C, Ross V, Mahadevan U. Micronutrient deficiencies in inflammatory bowel disease: from A to zinc. Inflamm Bowel Dis. 2012 Oct; 18(10):1961-81.

Esteve M, Mahadevan U, Sainz E, Rodriguez E, Salas A, Fernández-Bañares F. Efficacy of anti-TNF therapies in refractory severe microscopic colitis. J Crohns Colitis. 2011 Dec; 5(6):612-8.

Leung Y, Heyman MB, Mahadevan U. Transitioning the adolescent inflammatory bowel disease patient: guidelines for the adult and pediatric gastroenterologist. Inflamm Bowel Dis. 2011 Oct; 17(10):2169-73.

Mahadevan U, Cucchiara S, Hyams JS, Steinwurz F, Nuti F, Travis SP, Sandborn WJ, Colombel JF. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol. 2011 Feb; 106(2):214-23; quiz 224.

Broadhurst MJ, Leung JM, Kashyap V, McCune JM, Mahadevan U, McKerrow JH, Loke P. IL-22+ CD4+ T cells are associated with therapeutic trichuris trichiura infection in an ulcerative colitis patient. Sci Transl Med. 2010 Dec 01; 2(60):60ra88.

van der Woude CJ, Kolacek S, Dotan I, Oresland T, Vermeire S, Munkholm P, Mahadevan U, Mackillop L, Dignass A. European evidenced-based consensus on reproduction in inflammatory bowel disease. J Crohns Colitis. 2010 Nov; 4(5):493-510.

Kwan LY, Mahadevan U. Inflammatory bowel disease and pregnancy: an update. Expert Rev Clin Immunol. 2010 Jul; 6(4):643-57.

Dotan I, Rachmilewitz D, Schreiber S, Eliakim R, van der Woude CJ, Kornbluth A, Buchman AL, Bar-Meir S, Bokemeyer B, Goldin E, Maaser C, Mahadevan U, Seidler U, Hoffman JC, Homoky D, Plasse T, Powers B, Rutgeerts P, Hommes D. A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease. Gut. 2010 Jun; 59(6):760-6.

Hou JK, Velayos F, Terrault N, Mahadevan U. Viral hepatitis and inflammatory bowel disease. Inflamm Bowel Dis. 2010 Jun; 16(6):925-32.

El-Nachef N, Terdiman J, Mahadevan U. Anti-tumor necrosis factor therapy for inflammatory bowel disease in the setting of immunosuppression for solid organ transplantation. Am J Gastroenterol. 2010 May; 105(5):1210-1.

Baumgart DC, Targan SR, Dignass AU, Mayer L, van Assche G, Hommes DW, Hanauer SB, Mahadevan U, Reinisch W, Plevy SE, Salzberg BA, Buchman AL, Mechkov GM, Krastev ZA, Lowder JN, Frankel MB, Sandborn WJ. Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis. Inflamm Bowel Dis. 2010 Apr; 16(4):620-9.

Molloy JW, Kim E, Mahadevan U. Do side-by-side anastomoses decrease the risk of recurrence in Crohn's disease? Gastroenterology. 2010 May; 138(5):2010-2.

Sandborn WJ, Korzenik J, Lashner B, Leighton JA, Mahadevan U, Marion JF, Safdi M, Sninsky CA, Patel RM, Friedenberg KA, Dunnmon P, Ramsey D, Kane S. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology. 2010 Apr; 138(4):1286-96, 1296.e1-3.

Mahadevan U. Pregnancy and inflammatory bowel disease. Med Clin North Am. 2010 Jan; 94(1):53-73.

Mahadevan U, Kane S. Use of infliximab in pregnancy. Am J Gastroenterol. 2010 Jan; 105(1):219; author reply 219-20.

Mahadevan U. Pregnancy and inflammatory bowel disease. Gastroenterol Clin North Am. 2009 Dec; 38(4):629-49.

Sewell JL, Mahadevan U. Of blemishes and bowels: isotretinoin and inflammatory bowel disease. Gastroenterology. 2010 Jan; 138(1):392-4.

Mahadevan U. Cervical neoplasia risk in IBD: truth or hysteria? Inflamm Bowel Dis. 2009 Nov; 15(11):1619-20.

Moscandrew M, Mahadevan U, Kane S. General health maintenance in IBD. Inflamm Bowel Dis. 2009 Sep; 15(9):1399-409.

McCabe JM, Mahadevan U, Vidyarthi A. An obscure harbinger. Difficult diagnosis of Crohn's Disease. Am J Med. 2009 Jun; 122(6):516-8.

Sewell JL, Mahadevan U. A new answer to an old question: azathioprine withdrawal in quiescent Crohn's disease. Gastroenterology. 2009 Jul; 137(1):379-81.

Hou JK, Mahadevan U. A 24-year-old pregnant woman with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2009 Sep; 7(9):944-7.

Costouros NG, Niho H, Mahadevan U, Kerlan RK, Bloom AI. Angiographic embolization for control of life-threatening hemorrhage from benign rectal ulcers. J Vasc Interv Radiol. 2009 Apr; 20(4):561-2.

Thia KT, Mahadevan U, Feagan BG, Wong C, Cockeram A, Bitton A, Bernstein CN, Sandborn WJ. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2009 Jan; 15(1):17-24.

Sewell JL, Mahadevan U. Infliximab and surgical complications: truth or perception? Gastroenterology. 2009 Jan; 136(1):354-5.

Dubinsky M, Abraham B, Mahadevan U. Management of the pregnant IBD patient. Inflamm Bowel Dis. 2008 Dec; 14(12):1736-50.

Mahadevan U. Continuing immunomodulators and biologic medications in pregnant IBD patients - pro. Inflamm Bowel Dis. 2007 Nov; 13(11):1439-40.

Plevy S, Salzberg B, Van Assche G, Regueiro M, Hommes D, Sandborn W, Hanauer S, Targan S, Mayer L, Mahadevan U, Frankel M, Lowder J. A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. Gastroenterology. 2007 Nov; 133(5):1414-22.

Mahadevan U, Sandborn WJ, Li DK, Hakimian S, Kane S, Corley DA. Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology. 2007 Oct; 133(4):1106-12.

Velayos F, Mahadevan U. Management of steroid-dependent ulcerative colitis: immunomodulatory agents, biologics, or surgery? Clin Gastroenterol Hepatol. 2007 Jun; 5(6):668-71.

Mahadevan U. Gastrointestinal medications in pregnancy. Best Pract Res Clin Gastroenterol. 2007; 21(5):849-77.

Mahadevan U. TNF-alpha antagonists: benefits beyond remission. Rev Gastroenterol Disord. 2007; 7 Suppl 1:S13-9.

Mahadevan U. Fertility and pregnancy in the patient with inflammatory bowel disease. Gut. 2006 Aug; 55(8):1198-206.

Mahadevan U, Kane S. American gastroenterological association institute medical position statement on the use of gastrointestinal medications in pregnancy. Gastroenterology. 2006 Jul; 131(1):278-82.

Mahadevan U, Kane S. American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology. 2006 Jul; 131(1):283-311.

Mahadevan U. Pregnancy, Fertility, and Therapies for IBD. Gastroenterol Hepatol (N Y). 2006 Apr; 2(4):234-236.

Mahadevan U. Mucosal healing in Crohn's disease: what you see is what you get? Gastrointest Endosc. 2006 Mar; 63(3):443-4.

Mahadevan U, Terdiman JP, Aron J, Jacobsohn S, Turek P. Infliximab and semen quality in men with inflammatory bowel disease. Inflamm Bowel Dis. 2005 Apr; 11(4):395-9.

Gill KR, Mahadevan U. Infliximab for the treatment of metastatic hepatic and pulmonary Crohn's disease. Inflamm Bowel Dis. 2005 Feb; 11(2):210-2.

Mahadevan U. Medical treatment of ulcerative colitis. Clin Colon Rectal Surg. 2004 Feb; 17(1):7-19.

Mahadevan U. 6TG: when less is more than you bargained for. Inflamm Bowel Dis. 2003 Nov; 9(6):394-5.

Mathy C, Schneider K, Chen YY, Varma M, Terdiman JP, Mahadevan U. Gross versus microscopic pancolitis and the occurrence of neoplasia in ulcerative colitis. Inflamm Bowel Dis. 2003 Nov; 9(6):351-5.

Mahadevan U, Sandborn WJ. Diagnosis and management of pouchitis. Gastroenterology. 2003 May; 124(6):1636-50.

Mahadevan U, Loftus EV, Tremaine WJ, Pemberton JH, Harmsen WS, Schleck CD, Zinsmeister AR, Sandborn WJ. Azathioprine or 6-mercaptopurine before colectomy for ulcerative colitis is not associated with increased postoperative complications. Inflamm Bowel Dis. 2002 Sep; 8(5):311-6.

Mahadevan U, Loftus EV, Tremaine WJ, Sandborn WJ. Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am J Gastroenterol. 2002 Apr; 97(4):910-4.

  Select data provided by UCSF Profiles, powered by CTSI at UCSF. Learn more about the data source.